Advertisement

Topics

Omalizumab Benefits Patients With Chronic Inducible Urticaria

03:45 EDT 11 Aug 2017 | Medscape

The recombinant anti-immunoglobulin E (IgE) monoclonal antibody omalizumab has 'substantial benefits' in treating various forms of chronic inducible urticaria (CIndU), according to a new systematic review.
Reuters Health Information

Original Article: Omalizumab Benefits Patients With Chronic Inducible Urticaria

NEXT ARTICLE

More From BioPortfolio on "Omalizumab Benefits Patients With Chronic Inducible Urticaria"

Quick Search
Advertisement
 

Relevant Topics

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...